Streetbeat News

PLRZ

Polyrizon Ltd.

Industry

Biotechnology

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Polyrizon Ltd. has initiated preclinical studies for an intranasal Naloxone treatment aimed at combating opioid overdoses. This development leverages their innovative intranasal hydrogel platform.

Portfolio Pulse from

March 13, 2025 | 12:00 pm

Polyrizon Ltd., a biotech company listed on Nasdaq, has filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2024, with the SEC.

Portfolio Pulse from

March 11, 2025 | 8:45 pm

Polyrizon Ltd. (Nasdaq: PLRZ) has initiated preclinical studies for an intranasal Naloxone treatment targeting opioid overdoses, utilizing its T&T platform.

Portfolio Pulse from

March 10, 2025 | 12:00 pm

Polyrizon Ltd. has started the GMP manufacturing preliminary process for its PL-14 allergy blocker, with plans for a clinical trial in 2025. Eurofins CDMO Amatsiaquitaine S.A.S. will support Polyrizon in future commercialization efforts.

Portfolio Pulse from

January 23, 2025 | 12:00 pm

Polyrizon Ltd. has announced the publication of a U.S. national patent application for its innovative hydrogel nasal technologies, including Capture and Contain (C&C™) and Trap and Target (T&T™).

Portfolio Pulse from

December 30, 2024 | 11:45 am

Polyrizon Ltd. has appointed Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs to prepare for its upcoming clinical trial for PL-14 in 2025. Dr. Meir brings extensive experience in regulatory strategy and clinical affairs management.

Portfolio Pulse from

December 19, 2024 | 12:30 pm

Polyrizon has entered a manufacturing agreement with an EU-based GMP facility for its PL-14 Allergy Blocker, preparing for a 2025 clinical trial. The facility's large-scale capabilities will support future commercialization.

Portfolio Pulse from

December 18, 2024 | 11:45 am

Polyrizon Ltd. has appointed Asaf Azulay as VP of Regulatory Affairs and Quality Assurance, highlighting its commitment to high industry standards in developing intranasal hydrogels.

Portfolio Pulse from

December 13, 2024 | 11:45 am

Alphabet Inc. shares rose 6% in pre-market trading after reporting better-than-expected Q3 results with $88.27 billion in revenue. Other stocks like Haoxi Health Technology and Snap Inc. also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 30, 2024 | 10:16 am

Polyrizon shares resumed trading after a circuit breaker halt. The halt was likely triggered by significant price movement, which can indicate volatility or news impacting the stock.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 3:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.